Screener
Eli Lilly LLY Reportable Segment — Other segment items
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Early-stage research and development(1) | 1,450 | 1,156 | 2,715 | 2,146 |
| Late-stage research and development(1) | 2,368 | 2,180 | 4,613 | 3,924 |
| Marketing, selling, and administrative | 3,430 | 2,753 | 6,364 | 5,221 |
| Acquired in-process research and development | 2,776 | 154 | 3,360 | 1,726 |
| Other segment items(2) | 2,587 | 1,207 | 4,384 | 2,177 |
| Net income | $7,095 | $5,661 | $14,491 | $8,420 |
| Interest expense | $345 | $249 | $677 | $493 |
| Expenditures for long-lived assets(3) | 2,906 | 1,985 | 5,344 | 3,502 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's reportable segment — other segment items?
- Eli Lilly (LLY) reported reportable segment — other segment items of $2.59B in Q2 2026.
- How has Eli Lilly's reportable segment — other segment items changed year-over-year?
- Eli Lilly's reportable segment — other segment items increased by 114.3% year-over-year, from $1.21B to $2.59B.
- What is the long-term trend for Eli Lilly's reportable segment — other segment items?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — other segment items has grown at a 76.0% compound annual growth rate (CAGR), from $1.13B to $6.15B.
- What does reportable segment — other segment items mean?
- Encompasses miscellaneous income or expense items specific to the segment that do not fall under standard operating categories like COGS or SG&A. This may include restructuring charges, legal settlements, or non-recurring gains/losses unique to the segment's operations. It provides visibility into non-core operational impacts on segment performance.
Ask your AI about Eli Lilly's reportable segment — other segment items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude